Haploidentical Stem Cell Transplantation Utilizing T-Cell Depletion as Therapy for Patients With Refractory Hematological Malignancies

Inclusion Criteria:

Refractory hematological malignancies (chemoresistant relapse or
primary induction failure) including:

- Acute lymphoblastic leukemia (ALL), must have isolated or combined bone marrow
relapse or primary induction failure. Patients with extramedullary relapse are not
eligible unless they have previously received a stem cell transplant

- Acute myeloid leukemia (AML) >25% blasts in bone marrow

- Secondary AML

- Myelodysplastic syndrome (MDS)

- Secondary MDS

- Chronic myeloid leukemia (CML)

- Juvenile myelomonocytic leukemia (JMML)

- Paroxysmal nocturnal hemoglobinuria (PNH)

- Non-Hodgkin's lymphoma (NHL)*

- Hodgkin's Disease (HD)*

*Patients with lymphomas must have failed standard non-cross reactive combination
salvage chemotherapy with or without radiation therapy followed by autologous stem
cell transplant or patients with chemo resistant disease

- If patient has had previous stem cell transplant, must not be no earlier than 3
months from previous date of transplant

- Patients with shortening fraction greater than or equal to 25%

- Patients with creatinine clearance greater than or equal to 40cc/min/1.73m^2

- Patients with FVC greater than or equal to 40% of predicted, or pulse oximetry
greater than or equal to 92% on room air

- Patients with a performance score (Lansky/Karnofsky) of greater than or equal to 50

- Must have a suitable family member donor that is HIV negative, greater than or equal
to 18 years of age available for stem cell donation

Exclusion Criteria:

- Patients with a known allergy to murine products

- (Female Patients) Patient is pregnant

- Female Patients) Patient is lactating